Phase I dose escalation of LAVA-051, a novel bispecific γδ-T cell engager (Gammabody™), in relapsed/refractory hematological malignancies June 10, 2022June 10, 2022 European Hematological Association (EHA) 2022 Congress presentation Broijl, et al.